Featured Opinions
Living with Lupus: Breaking the Silence
Lupus is an almost invisible disease, yet can have considerable impact on patients' quality of life, but there is much that pharma can do to help
by James Wright
Many companies are actively working on the development of 'biobetters' - improved versions of originator biological drugs - but are these drugs worth the investment?
Seeing the Larger Picture on Patient Risk
In the era of value-based care, life science companies will be called upon to take on more risk for patient care – but how much risk are they willing to accept?
Thinking Machines: From Magic to Normal
With big data come big challenges - AI and big data have the potential to transform medicine but only if we keep an open dialogue about associated issues and challenges
Nutrition Market in Brazil: Growth Against the Odds
by Marc Yates
Economic change and rising health consciousness have lit a fuse under the Brazilian nutrition market
5 keys to Unlock Digital Transformation Success
by Will Reece
Digital transformation inside out and upside down
New Ways to Pay for Low-Priority Drug Trials
Companies cannot afford to conduct trials for every asset in their early-stage pipelines - unless they team up with new investors
by Jeff Elton
AI, machine learning and cognitive computing may be changing healthcare, but it's not all plain sailing.
The Time is Now to Move Far Beyond the Pill
Companies must change their mindset and embrace digital technologies if they are developing beyond-the-pill solutions that deliver real value
A Safe Place to Talk about Crohn's
Dealing with anxiety and embarrassment is a vital component of non-medical interventions in Crohn’s
This Chief Medical/Mum Officer is Not Waiting for Godot
It's time to stop waiting around - and breathe life into patient engagement
Women and men need to work together to create a gender-inclusive working world
Digital: Teaching An Old Dog New Tricks?
by Kevin Dolgin
Car maker Tesla has a few lessons for pharma on truly putting digital first
Patient-Centred Care; The Past, The Present, The Future
A manifesto to make patient engagement as simple as ABC
Why We Won’t Wait on Gender Equality
Will you #BeBoldForChange today, on International Women's Day 2017 and beyond?
Fresh Thinking Needed to Champion Female Talent
If you think we have achieved gender parity in the workplace, think again
Making Sense of Nutraceuticals in China
by Marc Yates
The Chinese nutraceuticals market remains some way from realizing its true potential
Egypt: Drug Price Hikes Highlight Market Volatility
Profitability in the Egyptian pharmaceutical industry remains constrained by tight price controls
The Future of the Pharma & Automotive Industry
There are more similarities between the two than you may think
Biosimilars: Bringing Patients into the Conversation
Sharing her ''Living With'' research results, new patient insights columnist Mariel Melcalfe discusses biosimilar awareness
Why the Current Approach to Commercial Model Innovation Won’t be Successful
by David Laws
The days of seeing the pill as the value the industry provides is gone, stakeholders are demanding more from pharma than ever.
Transparency around Value to Support Rational Pricing Discussions
Rising drug prices have been hotly debated this year with a greater push for pricing transparency.
Death and Taxes – The Certainty of Life
Farewell to 2016; where it seemed that every month brought another death of someone creative, political or relevant in the lexicon of life.
Nutraceuticals in India: A Challenging Opportunity
by Marc Yates
As growth begins to plateau in more established territories, attention is turning to emerging markets with a fast-expanding middle class.